Belatacept and long-term outcomes in kidney transplantation

New England Journal of Medicine

Volumn 374, Issue 4, 2016, Pages 333-433

  Vincenti, Flavio ^a   Rostaing, Lionel ^c   Grinyo, Joseph ^e   Rice, Kim ^f   Steinberg, Steven ^b   Gaite, Luis ^g   Moal, Marie Christine ^d   Mondragon Ramirez, Guillermo A ^h   Kothari, Jatin ⁱ   Polinsky, Martin S ^j   Meier Kriesche, Herwig Ulf ^j   Munier, Stephane ^j   Larsen, Christian P ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHARP MEMORIAL HOSPITAL   (United States)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g Clinica de Urologia y Nefrologia   (Argentina)

^h Instituto Mexicano de Trasplantes   (Mexico)

ⁱ P D HINDUJA NATIONAL HOSPITAL   (India)

^j BRISTOL MYERS SQUIBB   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CYCLOSPORIN; ABATACEPT; IMMUNOSUPPRESSIVE AGENT;

ACUTE PYELONEPHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CONGENITAL LYMPHATIC SYSTEM DISORDER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE BLIND PROCEDURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE; CLINICAL TRIAL; FOLLOW UP; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MORTALITY; MULTICENTER STUDY;

ABATACEPT; CYCLOSPORINE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; SINGLE-BLIND METHOD;

EID: 84955444904     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506027     Document Type: Article

References (39)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:Suppl 3:S1-S155.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62.
3. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-83.
4. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. Transplant Proc 1997;29:304-5.
5. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73:775-82.
6. Opelz G, Döhler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87:795-802.
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
8. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029-34.
9. Fellström B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005;79:1160-3.
10. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002;62:311-8.
11. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003;75:1291-5.
12. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012;23:2061-71.
13. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443-53.
14. Bestard O, Campistol JM, Morales JM, et al. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia 2012;32:374-84.
15. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014;11:CD010699.
16. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant 2012;12:554-62.
17. European Medicines Agency. Nulojix: European Public Assessment Report - summary for the public (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002098/human-med-001459.jsp&mid=WC0b01ac058001d124).
18. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535-46.
19. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-57.
20. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12:210-7.
21. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12:630-9.
22. Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013;13:2875-83.
23. Charpentier B, Medina Pestana JO, Del C Rial M, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013;13:2884-91.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
25. Florman S, Medina J, Rial M, et al. Final results from the BENEFIT-EXT trial: a 7 year follow-up of belatacept treated patients. Am J Transplant 2015;15:Suppl 3. abstract.
26. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999;68:1851-4.
27. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80:1233-43.
28. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012;93:73-81.
29. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013;95:410-7.
30. Nair R, Agrawal N, Lebaeau M, Tuteja S, Chandran PK, Suneja M. Late acute kidney transplant rejection: clinicopathological correlates and response to corticosteroid therapy. Transplant Proc 2009;41:4150-3.
31. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014;14:59-69.
32. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14.
33. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003;14:2980-4.
34. Silva HT Jr, Yang HC, Meier-Kriesche HU, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014;97:636-41.
35. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52.
36. Vítko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-30.
37. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;35:Suppl:37S-51S.
38. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998;65:1450-4.
39. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999;68:391-6.